U.S. GOLD CORP. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that U.S. GOLD CORP. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Apr 30, 2017 | $17.40M | Jul 31, 2017 |
| FY2016 | Apr 30, 2016 | $25.18M | Jul 29, 2016 |
| FY2015 | Apr 30, 2015 | $28.26M | Aug 13, 2015 |
| FY2014 | Apr 30, 2014 | $30.40M | Jul 29, 2014 |
| FY2013 | Apr 30, 2013 | $27.62M | Jul 29, 2013 |
| FY2012 | Apr 30, 2012 | $36.08M | Jul 27, 2012 |
| FY2012 | Apr 30, 2011 | $46.85M | Jul 27, 2012 |
| FY2012 | Apr 30, 2010 | $44.02M | Jul 27, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($20.56M) | Jul 29, 2025 |
| FY2025 | Apr 30, 2024 | ($6.90M) | Jul 29, 2025 |
| FY2024 | Apr 30, 2023 | ($7.61M) | Jul 29, 2024 |
| FY2023 | Apr 30, 2022 | ($13.93M) | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | ($12.39M) | Aug 15, 2022 |
| FY2021 | Apr 30, 2020 | ($5.25M) | Jul 29, 2021 |
| FY2020 | Apr 30, 2019 | ($8.05M) | Jul 13, 2020 |
| FY2019 | Apr 30, 2018 | ($13.66M) | Jul 26, 2019 |
| FY2018 | Apr 30, 2017 | ($4.15M) | Jul 30, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($13.01M) | Jul 29, 2025 |
| FY2025 | Apr 30, 2024 | ($7.26M) | Jul 29, 2025 |
| FY2024 | Apr 30, 2023 | ($9.40M) | Jul 29, 2024 |
| FY2023 | Apr 30, 2022 | ($14.95M) | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | ($12.39M) | Aug 15, 2022 |
| FY2021 | Apr 30, 2020 | ($5.69M) | Jul 29, 2021 |
| FY2019 | Apr 30, 2019 | ($7.61M) | Jul 26, 2019 |
| FY2019 | Apr 30, 2018 | ($8.26M) | Jul 26, 2019 |
| FY2018 | Apr 30, 2017 | ($4.15M) | Jul 30, 2018 |
| FY2017 | Apr 30, 2016 | ($1.24M) | Jul 31, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Apr 30, 2012 | $0 | Jul 27, 2012 |
| FY2012 | Apr 30, 2011 | $1.89M | Jul 27, 2012 |
| FY2012 | Apr 30, 2010 | $4.27M | Jul 27, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Apr 30, 2017 | $4.52M | Jul 31, 2017 |
| FY2016 | Apr 30, 2016 | $5.77M | Jul 29, 2016 |
| FY2015 | Apr 30, 2015 | $6.17M | Aug 13, 2015 |
| FY2014 | Apr 30, 2014 | $7.18M | Jul 29, 2014 |
| FY2013 | Apr 30, 2013 | $8.70M | Jul 29, 2013 |
| FY2012 | Apr 30, 2012 | $12.32M | Jul 27, 2012 |
| FY2012 | Apr 30, 2011 | $12.37M | Jul 27, 2012 |
| FY2012 | Apr 30, 2010 | $13.37M | Jul 27, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($9.87M) | Jul 29, 2025 |
| FY2025 | Apr 30, 2024 | ($7.08M) | Jul 29, 2025 |
| FY2024 | Apr 30, 2023 | ($8.69M) | Jul 29, 2024 |
| FY2023 | Apr 30, 2022 | ($12.58M) | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | ($8.59M) | Aug 15, 2022 |
| FY2021 | Apr 30, 2020 | ($3.90M) | Jul 29, 2021 |
| FY2020 | Apr 30, 2019 | ($5.67M) | Jul 13, 2020 |
| FY2019 | Apr 30, 2018 | ($6.99M) | Jul 26, 2019 |
| FY2018 | Apr 30, 2017 | ($3.40M) | Jul 30, 2018 |
| FY2017 | Apr 30, 2016 | ($489.0K) | Jul 31, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $6.2K | Jul 29, 2025 |
| FY2024 | Apr 30, 2023 | $177.5K | Jul 29, 2024 |
| FY2023 | Apr 30, 2022 | $179.0K | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | $43.0K | Aug 15, 2022 |
| FY2017 | Apr 30, 2016 | $21.0K | Jul 31, 2017 |
| FY2016 | Apr 30, 2015 | $29.0K | Jul 29, 2016 |
| FY2014 | Apr 30, 2013 | $6.0K | Jul 29, 2014 |
| FY2014 | Apr 30, 2012 | $232.0K | Jul 29, 2014 |
| FY2013 | Apr 30, 2011 | $478.0K | Jul 29, 2013 |
| FY2012 | Apr 30, 2010 | $573.0K | Jul 27, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $24.87M | Jul 29, 2025 |
| FY2025 | Apr 30, 2024 | $22.58M | Jul 29, 2025 |
| FY2024 | Apr 30, 2023 | $24.18M | Jul 29, 2024 |
| FY2023 | Apr 30, 2022 | $27.50M | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | $31.32M | Aug 15, 2022 |
| FY2021 | Apr 30, 2020 | $9.83M | Jul 29, 2021 |
| FY2020 | Apr 30, 2019 | $7.40M | Jul 13, 2020 |
| FY2019 | Apr 30, 2018 | $12.99M | Jul 26, 2019 |
| FY2018 | Apr 30, 2017 | $11.43M | Jul 30, 2018 |
| FY2017 | Apr 30, 2016 | $5.75M | Jul 31, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $13.28M | Jul 29, 2025 |
| FY2025 | Apr 30, 2024 | $5.12M | Jul 29, 2025 |
| FY2024 | Apr 30, 2023 | $5.33M | Jul 29, 2024 |
| FY2023 | Apr 30, 2022 | $4.28M | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | $823.7K | Aug 15, 2022 |
| FY2021 | Apr 30, 2020 | $326.2K | Jul 29, 2021 |
| FY2020 | Apr 30, 2019 | $249.0K | Jul 13, 2020 |
| FY2019 | Apr 30, 2018 | $286.1K | Jul 26, 2019 |
| FY2018 | Apr 30, 2017 | $180.5K | Jul 30, 2018 |
| FY2017 | Apr 30, 2016 | $2.86M | Jul 31, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $11.59M | Jul 29, 2025 |
| FY2025 | Apr 30, 2024 | $17.46M | Jul 29, 2025 |
| FY2025 | Apr 30, 2023 | $18.86M | Jul 29, 2025 |
| FY2024 | Apr 30, 2022 | $23.23M | Jul 29, 2024 |
| FY2023 | Apr 30, 2021 | $30.07M | Jul 31, 2023 |
| FY2022 | Apr 30, 2020 | $9.51M | Aug 15, 2022 |
| FY2021 | Apr 30, 2019 | $7.15M | Jul 29, 2021 |
| FY2020 | Apr 30, 2018 | $12.70M | Jul 13, 2020 |
| FY2019 | Apr 30, 2017 | $11.25M | Jul 26, 2019 |
| FY2018 | Apr 30, 2016 | $2.87M | Jul 30, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Apr 30, 2017 | $1.08M | Jul 31, 2017 |
| FY2016 | Apr 30, 2016 | $1.08M | Jul 29, 2016 |
| FY2015 | Apr 30, 2015 | $1.08M | Aug 13, 2015 |
| FY2014 | Apr 30, 2014 | $1.08M | Jul 29, 2014 |
| FY2013 | Apr 30, 2013 | $1.08M | Jul 29, 2013 |
| FY2012 | Apr 30, 2012 | $1.45M | Jul 27, 2012 |
| FY2012 | Apr 30, 2011 | $1.24M | Jul 27, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($93.41M) | Jul 29, 2025 |
| FY2025 | Apr 30, 2024 | ($72.85M) | Jul 29, 2025 |
| FY2024 | Apr 30, 2023 | ($65.95M) | Jul 29, 2024 |
| FY2024 | Apr 30, 2022 | ($58.34M) | Jul 29, 2024 |
| FY2023 | Apr 30, 2021 | ($44.41M) | Jul 31, 2023 |
| FY2021 | Apr 30, 2020 | ($31.59M) | Jul 29, 2021 |
| FY2020 | Apr 30, 2019 | ($26.28M) | Jul 13, 2020 |
| FY2019 | Apr 30, 2018 | ($18.23M) | Jul 26, 2019 |
| FY2018 | Apr 30, 2017 | ($4.57M) | Jul 30, 2018 |
| FY2017 | Apr 30, 2016 | ($25.71M) | Jul 31, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Apr 30, 2020 | $2.75M | Jul 13, 2020 |
| FY2020 | Apr 30, 2019 | $2.20M | Jul 13, 2020 |
| FY2019 | Apr 30, 2018 | $7.65M | Jul 26, 2019 |
| FY2018 | Apr 30, 2017 | $6.82M | Jul 30, 2018 |
| FY2018 | Apr 30, 2016 | $305.7K | Jul 30, 2018 |
| FY2017 | Apr 30, 2015 | $327.0K | Jul 31, 2017 |
| FY2016 | Apr 30, 2014 | $258.0K | Jul 29, 2016 |
| FY2014 | Apr 30, 2013 | $324.0K | Jul 29, 2014 |
| FY2014 | Apr 30, 2012 | $3.28M | Jul 29, 2014 |
| FY2014 | Apr 30, 2011 | $345.0K | Jul 29, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | (1) | Jul 29, 2025 |
| FY2025 | Apr 30, 2024 | 0 | Jul 29, 2025 |
| FY2024 | Apr 30, 2023 | 0 | Jul 29, 2024 |
| FY2023 | Apr 30, 2022 | (1) | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | (3) | Aug 15, 2022 |
| FY2015 | Apr 30, 2015 | (2) | Sep 11, 2015 |
| FY2015 | Apr 30, 2014 | (1) | Sep 11, 2015 |
| FY2014 | Apr 30, 2013 | (2) | Jul 29, 2014 |
| FY2014 | Apr 30, 2012 | (1) | Jul 29, 2014 |
| FY2013 | Apr 30, 2011 | (3) | Jul 29, 2013 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | (1) | Jul 29, 2025 |
| FY2025 | Apr 30, 2024 | 0 | Jul 29, 2025 |
| FY2024 | Apr 30, 2023 | 0 | Jul 29, 2024 |
| FY2023 | Apr 30, 2022 | (1) | Jul 31, 2023 |
| FY2015 | Apr 30, 2015 | (2) | Sep 11, 2015 |
| FY2015 | Apr 30, 2014 | (1) | Sep 11, 2015 |
| FY2014 | Apr 30, 2013 | (2) | Jul 29, 2014 |
| FY2014 | Apr 30, 2012 | (1) | Jul 29, 2014 |
| FY2013 | Apr 30, 2011 | (3) | Jul 29, 2013 |
| FY2012 | Apr 30, 2010 | (1) | Jul 27, 2012 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | 12.69M | Jul 29, 2025 |
| FY2025 | Apr 30, 2024 | 10.73M | Jul 29, 2025 |
| FY2024 | Apr 30, 2023 | 9.30M | Jul 29, 2024 |
| FY2023 | Apr 30, 2022 | 8.35M | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | 7.07M | Aug 15, 2022 |
| FY2021 | Apr 30, 2020 | 2.90M | Jul 29, 2021 |
| FY2020 | Apr 30, 2019 | 1.99M | Jul 13, 2020 |
| FY2019 | Apr 30, 2018 | 17.59M | Jul 26, 2019 |
| FY2018 | Apr 30, 2017 | 6.93M | Jul 30, 2018 |
| FY2017 | Apr 30, 2016 | 412,074 | Jul 31, 2017 |